NZ778399A - Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator - Google Patents
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorInfo
- Publication number
- NZ778399A NZ778399A NZ778399A NZ77839920A NZ778399A NZ 778399 A NZ778399 A NZ 778399A NZ 778399 A NZ778399 A NZ 778399A NZ 77839920 A NZ77839920 A NZ 77839920A NZ 778399 A NZ778399 A NZ 778399A
- Authority
- NZ
- New Zealand
- Prior art keywords
- relacorilant
- heteroaryl
- receptor modulator
- glucocorticoid receptor
- therapeutic uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809327P | 2019-02-22 | 2019-02-22 | |
| US201962814441P | 2019-03-06 | 2019-03-06 | |
| US201962833517P | 2019-04-12 | 2019-04-12 | |
| PCT/US2020/019167 WO2020172501A1 (en) | 2019-02-22 | 2020-02-21 | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ778399A true NZ778399A (en) | 2024-11-29 |
Family
ID=72141382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ778399A NZ778399A (en) | 2019-02-22 | 2020-02-21 | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US11058670B2 (https=) |
| EP (1) | EP3927345A4 (https=) |
| JP (2) | JP7789561B2 (https=) |
| KR (2) | KR20210118971A (https=) |
| CN (1) | CN113490496A (https=) |
| AU (1) | AU2020226863B2 (https=) |
| BR (1) | BR112021015129A2 (https=) |
| CA (1) | CA3131263C (https=) |
| CL (1) | CL2021002145A1 (https=) |
| IL (1) | IL285771A (https=) |
| MX (1) | MX2021010135A (https=) |
| NZ (1) | NZ778399A (https=) |
| PH (1) | PH12021552025A1 (https=) |
| SG (1) | SG11202108964YA (https=) |
| UA (1) | UA129592C2 (https=) |
| WO (1) | WO2020172501A1 (https=) |
| ZA (1) | ZA202105633B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| FI3897589T3 (fi) | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| ES3008837T3 (en) * | 2018-12-21 | 2025-03-25 | Corcept Therapeutics Inc | Treatment of hypercoagulopathy in cushing's syndrome by administration of a glucocorticoid receptor modulator |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN114907349A (zh) * | 2021-02-10 | 2022-08-16 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| US20230372312A1 (en) * | 2022-05-20 | 2023-11-23 | Corcept Therapeutics Incorporated | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| IL319657A (en) | 2022-10-06 | 2025-05-01 | Corcept Therapeutics Inc | Glucocorticoid receptor modulator formulations |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| AU2023403359A1 (en) * | 2022-11-30 | 2025-05-29 | Corcept Therapeutics Incorporated | Treatments for cushing's syndrome that do not significantly affect cardiac rhythms |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (https=) | 1954-11-30 | 1957-04-11 | ||
| CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| JPH09505030A (ja) | 1993-08-06 | 1997-05-20 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | ヒドロイソキノリン誘導体 |
| US5696130A (en) | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
| EP1512683B1 (en) | 1998-03-10 | 2011-08-31 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
| WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| US7238778B2 (en) | 2001-07-17 | 2007-07-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| AU2002319665B2 (en) | 2001-07-23 | 2006-09-21 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CN1665515A (zh) | 2002-07-02 | 2005-09-07 | 科塞普特治疗公司 | 治疗与干扰素α治疗相关的精神病的方法 |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| UA84881C2 (ru) | 2003-09-03 | 2008-12-10 | Уайт | Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его |
| PT1761497E (pt) | 2004-01-09 | 2008-09-25 | Corcept Therapeutics Inc | Azadecalinas moduladoras do receptor de glucocorticóides |
| AU2005217646A1 (en) | 2004-02-26 | 2005-09-09 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A novel cofactor that modulates steroid receptor activities |
| AU2005222421B2 (en) | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| EP1928840B1 (en) | 2005-04-05 | 2011-08-10 | F. Hoffmann-La Roche AG | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| WO2009058944A2 (en) | 2007-11-01 | 2009-05-07 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| US20120022121A1 (en) | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
| US20090156672A1 (en) | 2007-12-17 | 2009-06-18 | Northwestern University | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20100135956A1 (en) | 2008-11-21 | 2010-06-03 | Auspex Pharmaceuticals, Inc. | Steroid modulators of progesterone receptor and/or glucocorticoid receptor |
| ES2531040T3 (es) | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Formas sólidas y procedimiento de preparación |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| KR20130106378A (ko) | 2010-08-27 | 2013-09-27 | 코어셉트 쎄라퓨틱스, 잉크. | 피리딜-아민 융합된 아자데칼린 조절제 |
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| RS57157B1 (sr) | 2011-11-11 | 2018-07-31 | Gilead Apollo Llc | Acc inhibitori i njihove primene |
| EP3111950B1 (en) | 2012-02-24 | 2021-08-25 | The University of Chicago | Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
| US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| PT4119561T (pt) | 2012-05-25 | 2024-09-30 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona |
| FI3848027T3 (fi) * | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
| CN107530435A (zh) | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| IL297201A (en) | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| ES3008837T3 (en) * | 2018-12-21 | 2025-03-25 | Corcept Therapeutics Inc | Treatment of hypercoagulopathy in cushing's syndrome by administration of a glucocorticoid receptor modulator |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
-
2020
- 2020-02-21 JP JP2021549571A patent/JP7789561B2/ja active Active
- 2020-02-21 MX MX2021010135A patent/MX2021010135A/es unknown
- 2020-02-21 NZ NZ778399A patent/NZ778399A/en unknown
- 2020-02-21 BR BR112021015129-0A patent/BR112021015129A2/pt not_active Application Discontinuation
- 2020-02-21 US US16/797,421 patent/US11058670B2/en active Active
- 2020-02-21 KR KR1020217030352A patent/KR20210118971A/ko not_active Ceased
- 2020-02-21 EP EP20759882.2A patent/EP3927345A4/en active Pending
- 2020-02-21 UA UAA202105300A patent/UA129592C2/uk unknown
- 2020-02-21 SG SG11202108964YA patent/SG11202108964YA/en unknown
- 2020-02-21 WO PCT/US2020/019167 patent/WO2020172501A1/en not_active Ceased
- 2020-02-21 CA CA3131263A patent/CA3131263C/en active Active
- 2020-02-21 PH PH1/2021/552025A patent/PH12021552025A1/en unknown
- 2020-02-21 KR KR1020257016944A patent/KR20250076696A/ko active Pending
- 2020-02-21 AU AU2020226863A patent/AU2020226863B2/en active Active
- 2020-02-21 CN CN202080015826.9A patent/CN113490496A/zh active Pending
-
2021
- 2021-06-09 US US17/343,524 patent/US11590113B2/en active Active
- 2021-08-10 ZA ZA2021/05633A patent/ZA202105633B/en unknown
- 2021-08-13 CL CL2021002145A patent/CL2021002145A1/es unknown
- 2021-08-22 IL IL285771A patent/IL285771A/en unknown
-
2022
- 2022-12-20 US US18/084,866 patent/US11684612B2/en active Active
-
2023
- 2023-05-09 US US18/144,979 patent/US12097192B2/en active Active
- 2023-10-12 JP JP2023176874A patent/JP2024009951A/ja active Pending
-
2024
- 2024-07-19 US US18/777,823 patent/US20250009721A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022523376A (ja) | 2022-04-22 |
| US11684612B2 (en) | 2023-06-27 |
| ZA202105633B (en) | 2023-02-22 |
| US20210338643A1 (en) | 2021-11-04 |
| CN113490496A (zh) | 2021-10-08 |
| US11590113B2 (en) | 2023-02-28 |
| UA129592C2 (uk) | 2025-06-11 |
| US20250009721A1 (en) | 2025-01-09 |
| EP3927345A1 (en) | 2021-12-29 |
| MX2021010135A (es) | 2021-09-23 |
| US20230346756A1 (en) | 2023-11-02 |
| WO2020172501A1 (en) | 2020-08-27 |
| US20200268723A1 (en) | 2020-08-27 |
| EP3927345A4 (en) | 2022-12-21 |
| PH12021552025A1 (en) | 2022-08-22 |
| CA3131263C (en) | 2024-01-02 |
| AU2020226863A1 (en) | 2021-08-12 |
| IL285771A (en) | 2021-10-31 |
| SG11202108964YA (en) | 2021-09-29 |
| US12097192B2 (en) | 2024-09-24 |
| CA3131263A1 (en) | 2020-08-27 |
| KR20250076696A (ko) | 2025-05-29 |
| JP7789561B2 (ja) | 2025-12-22 |
| JP2024009951A (ja) | 2024-01-23 |
| AU2020226863B2 (en) | 2023-04-06 |
| KR20210118971A (ko) | 2021-10-01 |
| US11058670B2 (en) | 2021-07-13 |
| BR112021015129A2 (pt) | 2021-09-28 |
| US20230131372A1 (en) | 2023-04-27 |
| CL2021002145A1 (es) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ778399A (en) | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator | |
| D'Orleans-Juste et al. | Function of the endothelinB receptor in cardiovascular physiology and pathophysiology | |
| Versmissen et al. | Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension | |
| Kloner et al. | Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 α-blockers, doxazosin and tamsulosin in healthy normotensive men | |
| Peifer et al. | New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase | |
| Sakima et al. | Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1–7) at the nucleus tractus solitarii | |
| Uno et al. | Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo [3, 4-b] pyridin-1-yl) benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor | |
| WO2007112675A8 (fr) | Protéine de fusion du récepteur du vegf et son utilisation | |
| DE60040293D1 (de) | Verwendung von nikotin in der angiogenese und der vaskulogenese | |
| JP6751977B2 (ja) | 線維芽細胞増殖因子受容体の阻害剤及びそれらの使用 | |
| Degnan et al. | Discovery of (R)-4-(8-Fluoro-2-oxo-1, 2-dihydroquinazolin-3 (4 H)-yl)-N-(3-(7-methyl-1 H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl) piperidin-1-yl) propan-2-yl) piperidine-1-carboxamide (BMS-694153): A Potent Antagonist of the Human Calcitonin Gene-Related Peptide Receptor for Migraine with Rapid and Efficient Intranasal Exposure | |
| MX2022000279A (es) | Regimenes de antagonistas del receptor de estrogeno. | |
| Mbaki et al. | 5-HT2A receptor activation of the external urethral sphincter and 5-HT2C receptor inhibition of micturition: a study based on pharmacokinetics in the anaesthetized female rat | |
| Puxeddu et al. | Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia | |
| Conley et al. | The role of α1‐adrenoceptors and 5‐HT1A receptors in the control of the micturition reflex in male anaesthetized rats | |
| Oger-Roussel et al. | Bladder and erectile dysfunctions in the Type 2 diabetic Goto-Kakizaki rat | |
| Yuan et al. | Recent progress in discovery of novel AAK1 inhibitors: from pain therapy to potential anti-viral agents | |
| Wang et al. | Unraveling the promise of RET inhibitors in precision cancer therapy by targeting RET mutations | |
| Wagner et al. | Structure–activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis | |
| Kalsi et al. | Update on oral treatments for male erectile dysfunction | |
| S Calabro et al. | Recent advances in the treatment of neurogenic erectile dysfunction | |
| Pasternak et al. | Stimulation of glucose-dependent insulin secretion by a potent, selective sst3 antagonist | |
| Ledeboer et al. | 2-Aminopyrazolo [1, 5-a] pyrimidines as potent and selective inhibitors of JAK2 | |
| NZ336157A (en) | Heterocyclic carboxylic acid derivatives and use thereof as endothelin receptor antagonists | |
| Ji et al. | Duration by design: discovery of revefenacin, the first-in-class nebulized once-daily bronchodilator for the treatment of patients with COPD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |